JP2010509379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509379A5 JP2010509379A5 JP2009536625A JP2009536625A JP2010509379A5 JP 2010509379 A5 JP2010509379 A5 JP 2010509379A5 JP 2009536625 A JP2009536625 A JP 2009536625A JP 2009536625 A JP2009536625 A JP 2009536625A JP 2010509379 A5 JP2010509379 A5 JP 2010509379A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- formula
- conh
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 229920000728 polyester Polymers 0.000 claims 2
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N Cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010062060 Hyperlipidaemia Diseases 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- 229960002965 Pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- 201000002674 obstructive nephropathy Diseases 0.000 claims 1
- 229940096701 plain lipid modifying drugs HMG CoA reductase inhibitors Drugs 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- LFVRANFPFBGCPD-CFDCCIPKSA-N CCCC[C@](CC)(CS(c(cc1)c([C@H]2c3cccc(NC(N[C@@H]([C@@H]4O)O[C@H](COS(O)(O)=O)[C@@H](C)[C@@H]4OCc4ccccc4)=O)c3)cc1N(C)C)(=O)=O)[C@@H]2O Chemical compound CCCC[C@](CC)(CS(c(cc1)c([C@H]2c3cccc(NC(N[C@@H]([C@@H]4O)O[C@H](COS(O)(O)=O)[C@@H](C)[C@@H]4OCc4ccccc4)=O)c3)cc1N(C)C)(=O)=O)[C@@H]2O LFVRANFPFBGCPD-CFDCCIPKSA-N 0.000 description 2
- 0 CCCCC(*)(CS(c(c([C@]1c2cccc(NC(*C3OC(*)(*)C(C)(C)C(C)(C)C3=*)=O)c2)c2)ccc2N(C)C)(=O)=O)C1O Chemical compound CCCCC(*)(CS(c(c([C@]1c2cccc(NC(*C3OC(*)(*)C(C)(C)C(C)(C)C3=*)=O)c2)c2)ccc2N(C)C)(=O)=O)C1O 0.000 description 1
- RPZKKZRKMDBVND-FSPHGCPUSA-N CCCCC(CCCC)(CS(c(c([C@H]1c2cc(NC(NC([C@@H]([C@H]3OCc4ccccc4)O)O[C@H](COS(O)(=O)=O)[C@H]3O)=O)ccc2)c2)ccc2N(C)C)(=O)=O)[C@@H]1O Chemical compound CCCCC(CCCC)(CS(c(c([C@H]1c2cc(NC(NC([C@@H]([C@H]3OCc4ccccc4)O)O[C@H](COS(O)(=O)=O)[C@H]3O)=O)ccc2)c2)ccc2N(C)C)(=O)=O)[C@@H]1O RPZKKZRKMDBVND-FSPHGCPUSA-N 0.000 description 1
- ACGFUAUGMVHLCR-RTNCXNSASA-N CCCC[C@](CC)(CS(c(c([C@H]1c2cc(NC(N[C@@H]([C@@H]([C@H]3OCc4ccccc4)O)O[C@H](COS(O)(O)O)[C@H]3O)=O)ccc2)c2)ccc2N(C)C)(=O)=O)[C@@H]1O Chemical compound CCCC[C@](CC)(CS(c(c([C@H]1c2cc(NC(N[C@@H]([C@@H]([C@H]3OCc4ccccc4)O)O[C@H](COS(O)(O)O)[C@H]3O)=O)ccc2)c2)ccc2N(C)C)(=O)=O)[C@@H]1O ACGFUAUGMVHLCR-RTNCXNSASA-N 0.000 description 1
- MKEUYRSOYYXUAR-UUZXJHQBSA-N CCCC[C@](CC)(CS(c(cc1)c([C@H]2c3cccc(NC(N[C@@H]([C@@H](C4OCc5ccccc5)O)O[C@H](COS(O)(O)=O)[C@H]4O)=O)c3)cc1N(C)C)(=O)=O)[C@@H]2O Chemical compound CCCC[C@](CC)(CS(c(cc1)c([C@H]2c3cccc(NC(N[C@@H]([C@@H](C4OCc5ccccc5)O)O[C@H](COS(O)(O)=O)[C@H]4O)=O)c3)cc1N(C)C)(=O)=O)[C@@H]2O MKEUYRSOYYXUAR-UUZXJHQBSA-N 0.000 description 1
Claims (7)
- 式I
Xは、NHであり;
R1は、(C1−C6)−アルキルであり;
R2は、OHであり;
R2’は、Hであり;
R5’は、(C1−C6)−アルキレン−O−S(O)2−R6であり;
R3、R3’、R4、R4’、R5は、相互に独立してH、Cl、Br、I、OH、−(CH2)−OH、CF3、NO2、N3、CN、S(O)2−R6、O−S(O)2−R6、(C1−C6)−アルキレン−S(O)2−R6、(C1−C6)−アルキレン−O−S(O)2−R6、COOH、COO(C1−C6)アルキル、CONH2、CONH(C1−C6)アルキル、CON[(C1−C6)アルキル]2、(C1−C6)−アルキル、(C2−C6)−アルケニル、(C2−C6)−アルキニル、O−(C1−C6)−アルキル、ここでアルキル基中の1つ、2つ以上又は全ての水素は、フッ素によって置き換えられてもよく;
フェニル、−(CH2)−フェニル、−(CH2)n−フェニル、O−フェニル、O−(CH2)m−フェニル、−(CH2)−O−(CH2)m−フェニル、ここでフェニル環は、F、Cl、Br、I、OH、CF3、NO2、CN、OCF3、O−(C1−C6)−アルキル、(C1−C6)−アルキル、NH2、NH(C1−C6)−アルキル、N((C1−C6)−アルキル)2、SO2−CH3、COOH、COO−(C1−C6)−アルキル、CONH2によって1〜3回置換されてもよく;
ここで常に基R3、R3’、R4、R4’、R5、R5’の少なくとも1つは、−O−(CH2)m−フェニルの意味を有し、ここでフェニル環は、F、Cl、Br、I、OH、CF3、NO2、CN、OCF3、O−(C1−C6)−アルキル、(C1−C6)−アルキル、NH2、NH(C1−C6)−アルキル、N((C1−C6)−アルキル)2、SO2−CH3、COOH、COO−(C1−C6)−アルキル、CONH2によって1〜3回置換されてもよく;
R6は、H、OH、(C1−C6)−アルキル、NH2、NH(C1−C6)−アルキル、N((C1−C6)−アルキル)2であり;
nは、2、3、4、5、6であり;
mは、1、2、3、4、5、6である〕
の化合物及びその医薬上許容しうる塩。 - 請求項1〜3のいずれか1項に記載の式Iの化合物、及びシンバスタチン、フルバスタチン、プラバスタチン、ロバスタチン、アトロバスタチン、セリバスタチン及びロスバスタチンの群からの少なくとも1つ又はそれ以上のHMGCoA還元酵素阻害剤を含む医薬。
- 高脂血症を治療する薬剤を製造するための請求項1〜3のいずれか1項に記載の式Iの化合物の使用。
- 血清コレステロールレベルを低下させる薬剤を製造するための請求項1〜3のいずれか1項に記載の式Iの化合物の使用。
- 糖尿病を治療する薬剤を製造するための請求項1〜3のいずれか1項に記載の式Iの化合物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006053635.5 | 2006-11-14 | ||
DE102006053635A DE102006053635B4 (de) | 2006-11-14 | 2006-11-14 | Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
PCT/EP2007/009393 WO2008058628A1 (de) | 2006-11-14 | 2007-10-30 | Neue mit benzylresten substituierte 1,4-benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010509379A JP2010509379A (ja) | 2010-03-25 |
JP2010509379A5 true JP2010509379A5 (ja) | 2010-12-02 |
JP5301453B2 JP5301453B2 (ja) | 2013-09-25 |
Family
ID=39092812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009536625A Active JP5301453B2 (ja) | 2006-11-14 | 2007-10-30 | ベンジル基によって置換された新規な1,4−ベンゾチエピン1,1−ジオキシド誘導体、その製造方法、その化合物を含む医薬及びその使用 |
Country Status (38)
Country | Link |
---|---|
US (1) | US7956085B2 (ja) |
EP (1) | EP2084172B1 (ja) |
JP (1) | JP5301453B2 (ja) |
KR (1) | KR101489168B1 (ja) |
CN (1) | CN101535326B (ja) |
AR (2) | AR063786A1 (ja) |
AT (1) | ATE492554T1 (ja) |
AU (1) | AU2007321496B2 (ja) |
BR (1) | BRPI0718813B8 (ja) |
CA (2) | CA2865332C (ja) |
CL (1) | CL2007003262A1 (ja) |
CO (1) | CO6190534A2 (ja) |
CR (1) | CR10733A (ja) |
CY (1) | CY1111166T1 (ja) |
DE (2) | DE102006053635B4 (ja) |
DK (1) | DK2084172T3 (ja) |
EC (1) | ECSP099327A (ja) |
ES (1) | ES2358371T3 (ja) |
GT (1) | GT200900125A (ja) |
HK (1) | HK1137762A1 (ja) |
HR (1) | HRP20110197T1 (ja) |
IL (1) | IL198718A (ja) |
MA (1) | MA30883B1 (ja) |
MX (1) | MX2009003958A (ja) |
MY (1) | MY148429A (ja) |
NI (1) | NI200900076A (ja) |
NO (2) | NO342236B1 (ja) |
NZ (1) | NZ576762A (ja) |
PE (1) | PE20081493A1 (ja) |
PL (1) | PL2084172T3 (ja) |
PT (1) | PT2084172E (ja) |
RU (1) | RU2456282C2 (ja) |
SI (1) | SI2084172T1 (ja) |
SV (1) | SV2009003216A (ja) |
TN (1) | TN2009000180A1 (ja) |
TW (1) | TWI414530B (ja) |
UY (1) | UY30709A1 (ja) |
WO (1) | WO2008058628A1 (ja) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
ES2666726T3 (es) * | 2008-05-02 | 2018-05-07 | Sanofi-Aventis Deutschland Gmbh | Procedimiento para la obtención de derivados de 1,1-dióxido de 1,4-benzotiepina |
CN102316872B (zh) | 2008-11-26 | 2016-12-21 | 萨蒂奥根制药公司 | 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂 |
ES2552657T3 (es) * | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
JP2013538215A (ja) | 2010-08-31 | 2013-10-10 | エスエヌユー アールアンドディービー ファウンデーション | PPARδアゴニストの胎児再プログラミング用途 |
DK3400944T3 (da) | 2010-11-08 | 2020-10-12 | Albireo Ab | Ibat-inhibitorer til behandling af leversygdomme |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
PL2771003T3 (pl) * | 2011-10-28 | 2017-10-31 | Lumena Pharmaceuticals Llc | Inhibitory ponownego wykorzystania kwasów żółciowych do leczenia pediatrycznych cholestatycznych chorób wątroby |
CN104023718B (zh) * | 2011-10-28 | 2017-04-05 | 鲁美纳医药公司 | 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂 |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
WO2015199147A1 (ja) | 2014-06-25 | 2015-12-30 | 味の素株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
CA3011565C (en) | 2016-02-09 | 2024-01-02 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
EP3413878B1 (en) | 2016-02-09 | 2021-04-14 | Albireo AB | Oral cholestyramine formulation and use thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
JP7328207B2 (ja) | 2017-08-09 | 2023-08-16 | アルビレオ・アクチボラグ | コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用 |
EP3664781A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine granules, oral cholestyramine formulations and use thereof |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
SG11202012151XA (en) | 2018-06-20 | 2021-01-28 | Albireo Ab | Crystal modifications of odevixibat |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
KR20210057053A (ko) | 2018-08-23 | 2021-05-20 | 씨젠 인크. | 항-tigit 항체 |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
CN114096268A (zh) | 2019-02-12 | 2022-02-25 | 米鲁姆制药公司 | 用于增加患有胆汁淤积性肝病的儿科受试者的生长的方法 |
KR20220109450A (ko) | 2019-12-04 | 2022-08-04 | 알비레오 에이비 | 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의 이의 용도 |
EP4069359B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
CA3186857A1 (en) | 2020-08-03 | 2022-02-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
KR20230106651A (ko) | 2020-11-12 | 2023-07-13 | 알비레오 에이비 | 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트 |
JP2024500309A (ja) | 2020-12-04 | 2024-01-09 | アルビレオ エービー | ベンゾチア(ジ)アゼピン化合物および胆汁酸モジュレータとしてのその使用 |
WO2023203248A1 (en) | 2022-04-22 | 2023-10-26 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
US20230398125A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
WO2024121434A1 (en) | 2022-12-09 | 2024-06-13 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994391A (en) * | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19825804C2 (de) * | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
KR20040032937A (ko) * | 2001-08-22 | 2004-04-17 | 아벤티스 파마 도이칠란트 게엠베하 | 1, 4-벤조티에핀-1, 1-디옥시드 유도체 및 기타 활성물질을 함유하는 배합 제제 및 이의 용도 |
GB0121621D0 (en) * | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
BR0213501A (pt) | 2001-11-02 | 2004-08-24 | Searle Llc | Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
DE102005033099A1 (de) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
-
2006
- 2006-11-14 DE DE102006053635A patent/DE102006053635B4/de not_active Expired - Fee Related
-
2007
- 2007-10-30 CA CA2865332A patent/CA2865332C/en active Active
- 2007-10-30 NO NO20091893A patent/NO342236B1/no unknown
- 2007-10-30 MX MX2009003958A patent/MX2009003958A/es active IP Right Grant
- 2007-10-30 CA CA2669230A patent/CA2669230C/en active Active
- 2007-10-30 BR BRPI0718813A patent/BRPI0718813B8/pt active IP Right Grant
- 2007-10-30 DE DE502007006055T patent/DE502007006055D1/de active Active
- 2007-10-30 DK DK07819434.7T patent/DK2084172T3/da active
- 2007-10-30 SI SI200730487T patent/SI2084172T1/sl unknown
- 2007-10-30 PT PT07819434T patent/PT2084172E/pt unknown
- 2007-10-30 MY MYPI20091688A patent/MY148429A/en unknown
- 2007-10-30 JP JP2009536625A patent/JP5301453B2/ja active Active
- 2007-10-30 RU RU2009122470/04A patent/RU2456282C2/ru active
- 2007-10-30 EP EP07819434A patent/EP2084172B1/de active Active
- 2007-10-30 ES ES07819434T patent/ES2358371T3/es active Active
- 2007-10-30 PL PL07819434T patent/PL2084172T3/pl unknown
- 2007-10-30 AT AT07819434T patent/ATE492554T1/de active
- 2007-10-30 CN CN2007800424399A patent/CN101535326B/zh active Active
- 2007-10-30 AU AU2007321496A patent/AU2007321496B2/en active Active
- 2007-10-30 KR KR1020097009914A patent/KR101489168B1/ko active IP Right Grant
- 2007-10-30 NZ NZ576762A patent/NZ576762A/en unknown
- 2007-10-30 WO PCT/EP2007/009393 patent/WO2008058628A1/de active Application Filing
- 2007-11-12 AR ARP070105027A patent/AR063786A1/es active IP Right Grant
- 2007-11-12 UY UY30709A patent/UY30709A1/es unknown
- 2007-11-12 TW TW096142599A patent/TWI414530B/zh active
- 2007-11-12 PE PE2007001553A patent/PE20081493A1/es not_active Application Discontinuation
- 2007-11-13 CL CL200703262A patent/CL2007003262A1/es unknown
-
2009
- 2009-04-03 SV SV2009003216A patent/SV2009003216A/es unknown
- 2009-04-20 CR CR10733A patent/CR10733A/es not_active Application Discontinuation
- 2009-05-04 NI NI200900076A patent/NI200900076A/es unknown
- 2009-05-06 CO CO09045559A patent/CO6190534A2/es not_active Application Discontinuation
- 2009-05-08 TN TNP2009000180A patent/TN2009000180A1/fr unknown
- 2009-05-12 IL IL198718A patent/IL198718A/en active IP Right Grant
- 2009-05-12 MA MA31864A patent/MA30883B1/fr unknown
- 2009-05-13 GT GT200900125A patent/GT200900125A/es unknown
- 2009-05-13 EC EC2009009327A patent/ECSP099327A/es unknown
- 2009-05-14 US US12/465,911 patent/US7956085B2/en active Active
-
2010
- 2010-03-08 HK HK10102412.4A patent/HK1137762A1/xx unknown
-
2011
- 2011-02-04 CY CY20111100133T patent/CY1111166T1/el unknown
- 2011-03-17 HR HR20110197T patent/HRP20110197T1/hr unknown
-
2017
- 2017-07-12 AR ARP170101938A patent/AR109033A2/es unknown
-
2018
- 2018-04-11 NO NO20180497A patent/NO344589B1/no unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010509379A5 (ja) | ||
JP2008539268A5 (ja) | ||
JP2008539267A5 (ja) | ||
JP2007534702A5 (ja) | ||
JP2011527332A5 (ja) | ||
JP2008520662A5 (ja) | ||
JP2009530306A5 (ja) | ||
JP2002543185A5 (ja) | ||
RU2472783C2 (ru) | Аминные производные и их применение в бета-2-адренорецептор-опосредованных заболеваниях | |
JP2014502972A5 (ja) | ||
JP2010536766A5 (ja) | ||
JP2008512408A5 (ja) | ||
JP2010526025A5 (ja) | ||
JP2011513196A5 (ja) | ||
JP2013517322A5 (ja) | ||
NZ566788A (en) | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation | |
JP2010518090A5 (ja) | ||
JP2009519903A5 (ja) | ||
JP2006522035A5 (ja) | ||
JP2008542386A5 (ja) | ||
RU2008145971A (ru) | Производные 2-тиоксантина, действующие в качестве ингибиторов мро | |
JP2009539828A5 (ja) | ||
JP2011513410A5 (ja) | ||
JP2010155827A5 (ja) | ||
BRPI0510278A (pt) | método para produzir compostos, produto, e, composto |